Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen pAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail
Latest, Q2 2026
7
Period ended Jun 30, 2026
Change on a year earlier
+75.0%
4 in Q2 2025
History
5 quarters
Since Q2 2025
Sources
5
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 7 | +75.0% | Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 4 | – | Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 4 | – | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| Q3 2025 | Sep 30, 2025 | 1 | – | Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 4 | – | Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗ |
Cite this data
StockData. (2026). Amgen PAVBLU (aflibercept-ayyh — Eylea Biosimilar, Retinal Diseases) — Rest of World (ROW) product sales ($M) ($M), quarterly Q2 2025–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_pavblu_row
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.